Compare · ADVM vs AMGN
ADVM vs AMGN
Side-by-side comparison of Adverum Biotechnologies Inc. (ADVM) and Amgen Inc. (AMGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADVM and AMGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $188.67B, about 1240.2x ADVM ($152.1M).
- Over the past year, ADVM is up 47.4% and AMGN is up 20.5% - ADVM leads by 26.9 points.
- AMGN has hit the wire 19 times in the past 4 weeks while ADVM has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 7 for ADVM).
- Company
- Adverum Biotechnologies Inc.
- Amgen Inc.
- Price
- $4.37+2.58%
- $349.54+1.12%
- Market cap
- $152.1M
- $188.67B
- 1M return
- +2.10%
- +5.58%
- 1Y return
- +47.39%
- +20.50%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 1983
- News (4w)
- 0
- 19
- Recent ratings
- 7
- 25
Adverum Biotechnologies Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest ADVM
- SEC Form 15-12G filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF FINANCIAL OFFICER Rubinstein Linda M was granted 42,000 units of Common Stock - Performance Stock Units and exercised 48,750 shares at a strike of $4.20, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hong Soo
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)